225 Thousand compounds in stock
Original and unique
210 Million novel building blocks
Over 650 highly skillful chemists
Unique synthesis technologies
14 Billion REAL compounds and
Custom Library Synthesis
On site access to all Enamine stock BB’s
Highly flexible arrangements
2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from September 2020
24 September 2020
Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), has joined the Advanced Machine Learning for Innovative Drug Discovery (AIDD) program, funded by the European Union within the framework of the Marie-Skłodowska-Curie Actions (MSCA) with a budget of Euros 3.93 million. The project, coordinated by Helmholtz Zentrum München,Germany, brings together fifteen institutions from eleven countries in addition to the University of British Columbia (Canada) to train sixteen PhD students in close collaboration with associated partners from the USA, Australia, China, Israel and other countries and develop next generation AI and Machine Learning (ML) models and systems for drug discovery.
Read press release
17 September 2020
Enamine Ltd., a leading chemical research organization and producer of the world’s largest collections of novel building blocks (225,000+) and screening compound libraries (2,740,000+), today announced the release of the Coronavirus Library. The new screening library capitalizes on Enamine’s decades of chemical R&D, advanced library design expertise, and experience with creating focused antiviral libraries. Enamine is a participant of a global Open Science initiative “COVID Moonshot”, aimed at discovering novel therapeutics against
Read press release
15 April 2020
Today Enamine, a leading provider of small molecules and drug discovery services, Chemspace, an online catalog with the largest offer of small molecules to search and buy, and Blue Dolphin Lead Discovery, a research organization focused on a fee-for-service virtual screening, announced the launch of the collaboration to support drug discovery projects.
Read press release
We offer our unique compound libraries intended to reach a wide range of drug discovery purposes and agro/crop science projects. The recent scientific data and versatile advanced technologies in computational chemistry were applied to design our focused sets. The main features of our approach to library design based on medicinal chemistry inspection combined with high novelty and reasonable priced molecules with validated synthetic methods.
Our sets of high-quality small molecules aimed to meet the most sophisticated drug discovery projects with capabilities of the extremely fast hit-follow-up programs.
510 765 compounds
Collection of Fragments and Lead-like molecules
2 109 632 compounds
The largest source of good-quality chemicals for HTS screening
46 441 compounds
Subset of Novel and highly valuable molecules
680 million compounds
The largest enumerated database of synthetically feasible molecules
172 723 compounds
The largest Collection of in-stock Fragments
2 100 compounds
Collection of referred small molecules with carefully collected activity data
We offer comprehensive support in developing your hit compounds. Naturally such programs are realised most efficiently when biological actives originate from our screening collection. However, even if the hit compounds are from the collections of other vendors lead identification and optimization projects can proceed most productively in our hands. Sometimes for this we only need to synthesize first examples of the given chemical series and validate synthesis route.